Akebia to Present at the 16th Annual Needham Healthcare Conference

CAMBRIDGE, Mass.--()--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017, at 10:00 a.m. Eastern Time. The conference is being held at the Westin NY Grand Central Hotel in New York City.

A live audio webcast of the presentation will be available on the company's website at http://ir.akebia.com/events.cfm. Archived presentations will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.

Contacts

Akebia
Theresa McNeely, 617-844-6113
SVP, Corporate Communications
and Investor Relations
tmcneely@akebia.com

Recent Stories

RSS feed for Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.